| Recruiting | Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma Urothelial Carcinoma | N/A | 2026-05-31 |
| Not Yet Recruiting | Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Mo Breast Cancer | Phase 2 | 2026-05-01 |
| Recruiting | Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors Solid Tumors | — | 2026-04-14 |
| Not Yet Recruiting | Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Ca HER2-positive Breast Cancer | — | 2026-03-31 |
| Not Yet Recruiting | SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study Breast Cancer, HER2-positive Breast Cancer | Phase 2 | 2026-03-31 |
| Not Yet Recruiting | Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone Localized Small Cell Lung Cancer | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-lin Rectal Neoplasms Malignant | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Fistula | — | 2026-02-01 |
| Not Yet Recruiting | Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Rectal Cancer, Radiotherapy, PD-1 Inhibitor | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma (Skin Cancer) | — | 2026-02-01 |
| Not Yet Recruiting | Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity Breast Cancer | Phase 4 | 2026-02-01 |
| Not Yet Recruiting | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD Small Cell Lung Carcinoma | Phase 2 | 2026-01-31 |
| Recruiting | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With SCLC, Extensive Stage | Phase 1 | 2026-01-20 |
| Not Yet Recruiting | Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer, EGFR-TKI Sensitizing Mutation | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | Autologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal Cancer Rectal Cancer, Gut Microbiomes, Autologous Probiotic Transplantation | N/A | 2025-12-31 |
| Not Yet Recruiting | Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer, Perioperative | Phase 2 | 2025-11-30 |
| Not Yet Recruiting | Monarch Robotic Bronchoscopy for Lung Nodule ICG Dye Marking Before VATS Small Pulmonary Nodules, Pulmonary Nodule Localization, Lung Cancer (Suspected or Confirmed) | N/A | 2025-10-10 |
| Not Yet Recruiting | High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma | Phase 2 | 2025-10-01 |
| Not Yet Recruiting | A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases Breast Cancer, Brain Metastases, Leptomeningeal Metastasis | Phase 1 / Phase 2 | 2025-09-30 |
| Not Yet Recruiting | Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy | Phase 2 | 2025-09-30 |
| Not Yet Recruiting | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Ce Renal Cell Carcinoma (RCC) | Phase 3 | 2025-09-25 |
| Recruiting | Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach Hepatoid Adenocarcinoma of Stomach | Phase 2 | 2025-09-18 |
| Not Yet Recruiting | Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor Esophageal Squamous Cell Carcinoma (ESCC) | — | 2025-09-01 |
| Not Yet Recruiting | Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI Classification Complication,Postoperative, Stoma | — | 2025-08-15 |
| Not Yet Recruiting | QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Phase 2 | 2025-07-15 |
| Not Yet Recruiting | Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Breast-Conserving Surgery, Breast Carcinoma, Margins in the Specimen | N/A | 2025-07-01 |
| Not Yet Recruiting | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma | Phase 1 | 2025-07-01 |
| Not Yet Recruiting | Evaluating AI and Human Expert Decisions in Colorectal Cancer Colorectal Cancer | — | 2025-07-01 |
| Not Yet Recruiting | Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM Colorectal Cancer Metastatic | — | 2025-07-01 |
| Recruiting | A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elde Lung Cancers | N/A | 2025-06-13 |
| Not Yet Recruiting | Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Live Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver | Phase 2 | 2025-06-01 |
| Not Yet Recruiting | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Adva Small Cell Lung Cancer | Phase 2 | 2025-06-01 |
| Recruiting | Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach Hepatoid Adenocarcinoma of Stomach | Phase 2 | 2025-05-20 |
| Recruiting | A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | 2025-05-15 |
| Not Yet Recruiting | 68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy Cancer | — | 2025-05-01 |
| Recruiting | Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and B TNBC | — | 2025-05-01 |
| Recruiting | A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Esophageal Cancer | Phase 2 | 2025-04-30 |
| Recruiting | Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Non Small Cell Lung Cancer NSCLC | Phase 1 / Phase 2 | 2025-04-08 |
| Recruiting | Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD NSCLC | N/A | 2025-04-06 |
| Recruiting | Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. Locally Advanced Rectal Cancer | N/A | 2025-04-01 |
| Recruiting | A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy Esophageal Cancer (EsC) | Phase 2 | 2025-03-31 |
| Recruiting | A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients W NK/T Cell Lymphoma | Phase 2 | 2025-03-21 |
| Recruiting | Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCL Non-Small Cell Lung Cancer | Phase 2 | 2025-03-01 |
| Recruiting | Trop-2 Targeted PET Probes in Advanced TNBC TNBC - Triple-Negative Breast Cancer | N/A | 2025-03-01 |
| Recruiting | Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Usin Limited-stage Small Cell Lung Cancer (LS-SCLC) | — | 2025-02-25 |
| Not Yet Recruiting | Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limi Small Cell Lung Cancer, Limited Stage, Hyperfractionated Accelerated Radiotherapy, Simultaneous Radiotherapy and Chemotherapy | Phase 2 | 2025-02-01 |
| Not Yet Recruiting | Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherap SCLC, Extensive Stage, Immunotherapy, Chemotherapy | Phase 2 | 2025-02-01 |
| Not Yet Recruiting | Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD NSCLC, Stage I, II, IIIA, IIIB | Phase 2 | 2025-01-15 |
| Not Yet Recruiting | TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors Solid Tumors | — | 2025-01-06 |
| Completed | First Human Trial of Targeting MDM2/MDMX PET Imaging MDM2/MDMX Gene Mutation, Nuclear Medicine, Positron Emission Tomography Imaing | EARLY_Phase 1 | 2025-01-03 |
| Recruiting | Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy Breast Cancer | N/A | 2025-01-01 |
| Not Yet Recruiting | CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors Solid Tumor | — | 2025-01-01 |
| Not Yet Recruiting | Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer Thrombopenia, Cervical Cancer, Radiotherapy Side Effect | Phase 2 | 2025-01-01 |
| Not Yet Recruiting | MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors Solid Tumor | — | 2025-01-01 |
| Not Yet Recruiting | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | 2024-12-30 |
| Recruiting | Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeuti Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy | — | 2024-12-01 |
| Not Yet Recruiting | Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Mo Breast Cancer | N/A | 2024-12-01 |
| Recruiting | Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions Lung Cancer, Non-Small Cell, Lung Infection | — | 2024-11-21 |
| Not Yet Recruiting | EGFR Mutation Targeting Molecular Probe for PET Imaging Cancer | — | 2024-11-15 |
| Recruiting | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors Advanced Malignant Solid Tumors | Phase 1 | 2024-11-14 |
| Not Yet Recruiting | Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC Lung Cancer, Non-Small Cell | — | 2024-11-10 |
| Not Yet Recruiting | The Role and Safety of Radiofrequency Ablation in Recurrent Liver Metastasis of Colorectal Cancer Colo-rectal Cancer, Liver Metastasis | N/A | 2024-10-01 |
| Recruiting | A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens Neuroendocrine Neoplasm | Phase 1 | 2024-09-29 |
| Recruiting | 68Ga-ICAM-1pep PET/CT in Cancer Patients Cancer | EARLY_Phase 1 | 2024-09-20 |
| Recruiting | Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study Breast Cancer, Brain Metastases From Breast Cancer, Trop2 | — | 2024-08-01 |
| Not Yet Recruiting | A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma Renal Cell Carcinoma | Phase 1 / Phase 2 | 2024-07-20 |
| Recruiting | Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer Esophageal Cancer, Gastric Cancer, Precision Screening | N/A | 2024-06-25 |
| Unknown | Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with 99mTc-3PRGD2 Probe. Stomach Neoplasm, Lymph Node Metastasis, RADIONUCLIDE IMAGING | N/A | 2024-06-06 |
| Recruiting | HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC HER2 Positive or Suspicious Positive Tumors | N/A | 2024-06-01 |
| Not Yet Recruiting | Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally A Rectal Cancer | Phase 2 / Phase 3 | 2024-06-01 |
| Not Yet Recruiting | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma Melanoma, Mucosal Melanoma, Metastatic Melanoma | Phase 1 | 2024-05-21 |
| Recruiting | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | 2024-05-16 |
| Unknown | Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors Solid Tumor | N/A | 2024-05-01 |
| Recruiting | The Efficacy and Safety of Liangxue Ointment in the Treatment of Hand-foot Syndrome Caused by VEGFR-TKI Drugs Hand-Foot Syndrome | N/A | 2024-03-25 |
| Recruiting | A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | 2024-03-14 |
| Recruiting | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma Collecting Duct Carcinoma | Phase 2 | 2024-02-09 |
| Recruiting | Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer Rectal Cancer | N/A | 2024-01-17 |
| Recruiting | A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy MSS Metastatic Colorectal Cancers, MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy | — | 2024-01-10 |
| Recruiting | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC Unresectable Hepatocellular Carcinoma | Phase 2 | 2024-01-01 |
| Recruiting | Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors B7H3, CD276 Affibody, PET/CT Imaing | EARLY_Phase 1 | 2024-01-01 |
| Recruiting | Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Phase 2 | 2023-11-01 |
| Unknown | the Beijing Randomized Study Of Prostate Cancer Screening Prostate Cancer | N/A | 2023-10-31 |
| Recruiting | KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer Colorectal Cancer | Phase 2 | 2023-10-26 |
| Recruiting | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade Digestive System Cancers | Phase 2 | 2023-10-25 |
| Unknown | Registry Study in MSI/dMMR Solid Tumors DMMR Cancer, MSI-H, Solid Tumor | — | 2023-10-07 |
| Not Yet Recruiting | KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer | Phase 2 | 2023-08-15 |
| Unknown | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Pros Metastatic Castration-resistant Prostate Cancer | Phase 2 | 2023-08-01 |
| Recruiting | Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy Advanced Malignant Neoplasm | EARLY_Phase 1 | 2023-07-06 |
| Unknown | To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infus Colorectal Liver Metastases (CRCLM) | — | 2023-07-01 |
| Unknown | Hyper-ERAS Program for Highly Selective Colorectal Cancer Patients Colorectal Cancer, ERAS | N/A | 2023-06-01 |
| Recruiting | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC Unresectable Hepatocellular Carcinoma, Oligometastatic Disease | Phase 2 | 2023-06-01 |
| Unknown | Outcomes of Endoscopic Operation in COVID-19 Infection: Cohort Study. COVID-19, Surgery-Complications | — | 2023-05-31 |
| Unknown | The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases Colorectal Liver Metastases | Phase 2 | 2023-05-30 |
| Active Not Recruiting | Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-n Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer | — | 2023-05-01 |
| Unknown | The Value of MRI in Assessing the Status of Retroperitoneal Resection Margin in Colon Cancer Colon Cancer | N/A | 2023-04-02 |
| Recruiting | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) Rectal Cancer | Phase 3 | 2023-03-29 |
| Recruiting | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma Acral Melanoma | Phase 3 | 2023-03-21 |
| Unknown | Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastri Gastric Cancer, Gastric Adenocarcinoma | — | 2023-03-01 |
| Unknown | Computation Prediction of Drug Response Based on Omics Data Breast Cancer | — | 2023-02-15 |
| Recruiting | Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors | EARLY_Phase 1 | 2023-02-06 |
| Unknown | Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma Soft Tissue Sarcoma | Phase 2 | 2023-02-01 |
| Unknown | Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma B-cell Lymphoma | Phase 2 | 2023-01-03 |
| Unknown | The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arte Advanced Hepatocellular Carcinoma (HCC) | — | 2023-01-01 |
| Unknown | Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer NSCLC | — | 2022-11-25 |
| Recruiting | Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer Colon Cancer, Circulating Tumor DNA | N/A | 2022-11-01 |
| Unknown | Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma Melanoma | N/A | 2022-10-27 |
| Unknown | Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer Breast Neoplasm Female | Phase 2 | 2022-10-20 |
| Recruiting | Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe Cancer | — | 2022-10-01 |
| Recruiting | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma Melanoma, Acral Melanoma, Temozolomide | Phase 2 | 2022-09-13 |
| Unknown | A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Can Non Small Cell Lung Cancer | Phase 2 | 2022-08-17 |
| Unknown | PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor Lung Cancer, Colorectal Cancer | N/A | 2022-07-15 |
| Recruiting | Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC P Non-small Cell Lung Cancer, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation | Phase 2 | 2022-07-07 |
| Recruiting | CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors Solid Tumor | N/A | 2022-06-23 |
| Completed | Attitudes and Technical Maneuvers Regarding Enterostomy Management and Stoma Creation Among Surgeons Colorectal Neoplasms, Colorectal Surgery | — | 2022-06-19 |
| Unknown | Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma Positron-Emission Tomography | — | 2022-06-01 |
| Completed | Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance SCLC,Extensive Stage | — | 2022-03-29 |
| Unknown | Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer | Phase 2 | 2022-02-25 |
| Unknown | Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC Breast Neoplasm Female | Phase 2 | 2021-12-25 |
| Unknown | PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor Lung Cancer, Melanoma, PD-L1 | N/A | 2021-12-09 |
| Unknown | Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma Melanoma | Phase 2 | 2021-11-01 |
| Recruiting | A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S Non-Small Cell Lung Cancer | Phase 2 | 2021-10-25 |
| Unknown | Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer ALK Positive, NSCLC Stage IIIB, NSCLC Stage IV | — | 2021-10-19 |
| Unknown | To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma Melanoma | Phase 2 | 2021-10-09 |
| Unknown | Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasi Melanoma Stage IV | Phase 1 | 2021-10-01 |
| Unknown | Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis Melanoma Stage IV | Phase 1 | 2021-10-01 |
| Completed | 68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy Cancer | Phase 1 / Phase 2 | 2021-09-22 |
| Unknown | cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC HCC, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy | — | 2021-09-10 |
| Recruiting | PD-L1 Targeting Molecular Imaging of Solid Tumors Gastrointestinal Tumors | N/A | 2021-07-20 |
| Unknown | CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors Gastrointestinal Cancer | N/A | 2021-05-13 |
| Unknown | Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positi HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab, Trastuzumab Combined With Pertuzumab and Chemotherapy | — | 2021-05-10 |
| Unknown | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors HER2-negative Breast Cancer, Gastric Adenocarcinoma, Cholangiocarcinoma | Phase 1 | 2021-04-01 |
| Unknown | Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab an Hepatocellular Carcinoma | Phase 2 | 2021-04-01 |
| Unknown | Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Advanced Non-squamous Non-small Cell Lung Cancer | — | 2021-03-03 |
| Unknown | Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC Non Small Cell Lung Cancer | — | 2021-03-03 |
| Unknown | Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut Advanced Melanoma | Phase 2 | 2021-01-26 |
| Unknown | [Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients Prostate Cancer | N/A | 2021-01-15 |
| Unknown | Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma Mucosal Melanoma, Neoadjuvant Treatment | Phase 2 | 2020-12-30 |
| Unknown | A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC. Locally Advanced NSCLC | Phase 2 | 2020-12-18 |
| Active Not Recruiting | PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer Prostate Cancer | N/A | 2020-10-22 |
| Unknown | TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC Transarterial Chemoembolization, Hepatocellular Carcinoma | Phase 2 | 2020-10-20 |
| Unknown | The Role of TCM on ERAS of Rectal Cancer Patients Rectal Cancer | Phase 2 | 2020-09-28 |
| Unknown | Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI Positron-Emission Tomography, Magnetic Resonance Imaging | — | 2020-09-15 |
| Unknown | The Molecular Imaging Research of F-18 Labeled DX600 PET Probe Solid Tumor | N/A | 2020-09-11 |
| Completed | The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma HCC | Phase 2 | 2020-09-11 |
| Recruiting | Research for the Molecular Imaging of the HER2 Targeting Tracer HER2 Positive or Suspicious Positive Tumors | N/A | 2020-09-07 |
| Unknown | 99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients Cancer | N/A | 2020-09-01 |
| Completed | HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma Hepatic Arterial Infusion Chemotherapy, Liver Metastases, Esophageal Squamous Cell Carcinoma | Phase 1 | 2020-06-18 |
| Completed | Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients Solid Tumor | N/A | 2020-06-13 |
| Unknown | To Identify KRAS Gene and Safe Margin in Association With Outcome in Colorectal Liver Metastases Following Ult KRAS Gene, Colorectal Cancer, Liver Metastasis | — | 2020-06-01 |
| Unknown | Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study Mucosal Melanoma | Phase 2 | 2020-05-30 |
| Unknown | Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Canc Rectum Cancer | — | 2020-05-25 |
| Unknown | Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantige Rectal Cancer | Phase 2 | 2020-05-25 |
| Unknown | Establishment of MRI Model for pTRG in Rectal Cancer With Establishment of Rectal Cancer | — | 2020-05-18 |
| Unknown | Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma Melanoma | Phase 2 | 2020-05-01 |
| Unknown | Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma Tumor, Solid, Positron-Emission Tomography, Lymphoma | N/A | 2020-05-01 |
| Unknown | The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma Melanoma | Phase 1 | 2020-05-01 |
| Unknown | RSYR for Fatigue Reduction in Cancer Fatigue Caused by Chemotherapy Cancer-related Problem/Condition | Phase 2 | 2020-04-02 |
| Unknown | A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects Urothelial Carcinoma | Phase 1 / Phase 2 | 2020-02-15 |
| Unknown | Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC Non-small Cell Lung Cancer | Phase 2 | 2019-12-31 |
| Unknown | Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma Advanced Mucosal Melanoma | Phase 2 | 2019-11-11 |
| Unknown | Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions Mild Dysplasia of Esophagus, Moderate Dysplasia of Esophagus, Severe Dysplasia of Esophagus | N/A | 2019-10-18 |
| Unknown | Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer Tumor, Solid, Positron-Emission Tomography, Colorectal Cancer | N/A | 2019-10-16 |
| Unknown | Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas PET/MRI | — | 2019-10-15 |
| Unknown | The Performance of Multi-tracer Multimodality PET in Lymphoma Positron-Emission Tomography | — | 2019-09-15 |
| Recruiting | Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma Gastric Adenocarcinoma | N/A | 2019-09-10 |
| Active Not Recruiting | Research for the Molecular Imaging of the PD-L1 Targeting Tracer Solid Tumor, Lung Cancer | N/A | 2019-08-06 |
| Unknown | Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma Mucosal Melanoma | Phase 2 | 2019-08-06 |
| Unknown | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC Carcinoma, Non-Small-Cell Lung, Docetaxel, Nivolumab | Phase 2 | 2019-07-08 |
| Completed | Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases Liver Metastases, Colorectal Cancer, Surgery | — | 2019-06-18 |
| Unknown | Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Mela Melanoma | Phase 1 | 2019-05-27 |
| Unknown | Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma | Phase 1 | 2019-05-13 |
| Unknown | Nab-PCE vs PC for MM After Failure of Anti-PD-1 Advanced Melanoma | Phase 2 | 2019-03-23 |
| Unknown | PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma Melanoma | Phase 2 | 2019-03-05 |
| Unknown | Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer Rectal Cancer | Phase 2 | 2019-03-01 |
| Unknown | Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer Breast Cancer | Phase 2 | 2019-02-21 |
| Completed | Preliminary Study on Eye Features of Patients With Malignant Tumors Feature Elongation, Cancer Patients | — | 2019-02-01 |
| Completed | Study on the Applicability of CCR Criteria in Rectal Cancer PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy, Immunotherapy | — | 2019-01-01 |
| Unknown | Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy Gastric Cancer, GastroEsophageal Cancer | N/A | 2019-01-01 |
| Unknown | Anlotinib in Treatment of Recurrent Small Cell Lung Cancer Recurrent Small Cell Lung Cancer | Phase 2 | 2018-11-01 |
| Unknown | Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC Gastric Cancer, Gastrectomy, Laparoscopic Surgery | N/A | 2018-07-01 |
| Unknown | Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy QOL; Quality of Life;Gastric Cancer; Gastrectomy;Neoadjuvant Chemotherapy | — | 2018-04-17 |
| Completed | Development of Artificial Intelligence System for Detection and Diagnosis of Breast Lesion Using Mammography Women With Breast Cancer | — | 2018-04-05 |
| Unknown | Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations Melanoma | Phase 2 | 2018-03-30 |
| Unknown | A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma Advanced Melanoma | Phase 2 | 2018-01-08 |
| Unknown | SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Colorectal Cancer Stage III, Adjuvant Chemotherapy | Phase 3 | 2018-01-01 |
| Unknown | Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma | Phase 2 | 2018-01-01 |
| Completed | Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer Gastric Cancer | — | 2017-11-22 |
| Unknown | Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer Esophageal Cancer | — | 2017-09-20 |
| Completed | Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer Lung Cancer Metastatic | Phase 2 | 2017-08-14 |
| Unknown | Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China Breast Cancer | — | 2017-07-20 |
| Unknown | Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) Adjuvant Chemotherapy | Phase 3 | 2017-06-01 |
| Unknown | Drug Sensitivity Screening for Gastrointestinal Cancer Gastrointestinal Cancer Metastatic | N/A | 2017-05-01 |
| Terminated | Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer Gastric Cancer | Phase 3 | 2017-04-24 |
| Unknown | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma Lymphoma, T-Cell, Peripheral | N/A | 2017-03-01 |
| Unknown | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Ly Lymphoma, T-Cell, Peripheral | N/A | 2017-03-01 |
| Unknown | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma Lymphoma, Extranodal NK-T-Cell | N/A | 2017-03-01 |
| Unknown | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cel Lymphoma, Extranodal NK-T-Cell | N/A | 2017-03-01 |
| Completed | Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics Esophagus Cancer | — | 2017-02-15 |
| Available | The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules Thyroid Nodules | — | 2016-12-01 |
| Unknown | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma, Large B-Cell, Diffuse | N/A | 2016-10-01 |
| Unknown | Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer Malignant Pleural Effusion | Phase 2 | 2016-10-01 |
| Unknown | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma Lymphoma, Large B-Cell, Diffuse | N/A | 2016-10-01 |
| Unknown | Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma Melanoma | Phase 2 | 2016-10-01 |
| Completed | Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatmen Rectal Cancer | — | 2016-08-01 |
| Completed | Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rec Rectal Cancer | Phase 2 | 2016-08-01 |
| Completed | Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006) Breast Cancer | Phase 2 | 2016-05-01 |
| Unknown | A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST Gastrointestinal Stromal Tumor | N/A | 2016-05-01 |
| Completed | Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma Esophageal Cancer | N/A | 2016-04-01 |
| Completed | Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Colorectal Cancer Stage IV, Metastasis | Phase 2 / Phase 3 | 2016-01-01 |
| Unknown | A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients Melanoma | Phase 1 | 2015-10-01 |
| Unknown | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2015-10-01 |
| Unknown | Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Neurotoxicity | Phase 2 | 2015-07-01 |
| Completed | RSYR for Fatigue Reduction in Cancer Survivors Cancer-related Problem/Condition | Phase 2 | 2015-06-01 |
| Unknown | A Trial on Contrast-enhanced Ultrasound Versus Conventional Ultrasound Guided Biopsy of Liver Neoplasms Liver Neoplasms | N/A | 2015-04-01 |
| Unknown | A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carc Metastatic Renal Cell Carcinoma | Phase 2 | 2015-03-01 |
| Unknown | Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection Hepatocellular Carcinoma | Phase 2 / Phase 3 | 2015-02-01 |
| Unknown | Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Pati Metastatic Renal Cell Carcinoma | Phase 2 | 2014-12-01 |
| Unknown | Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive S Gastrointestinal Neoplasms | Phase 1 / Phase 2 | 2014-10-01 |
| Unknown | Blood Detection of EGFR Mutation For Iressa Treatment Lung Adenocarcinoma | N/A | 2014-10-01 |
| Unknown | Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) Small Cell Lung Cancer Extensive Stage | Phase 2 | 2014-09-01 |
| Unknown | Endoscopic Ultrasound in Detailed T-staging of Upper GI Malignancies in Vitro Gastrointestinal Neoplasms | — | 2014-06-01 |
| Unknown | The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma Liver Neoplasms | N/A | 2014-05-22 |
| Unknown | Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric Cancer Gastric Cancer | N/A | 2014-03-01 |
| Unknown | HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Melanoma | Phase 3 | 2014-02-01 |
| Unknown | Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma Melanoma | Phase 2 | 2013-12-01 |
| Unknown | Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study Melanoma, TOR Serine-Threonine Kinases, Neoplasm Metastasis | Phase 2 | 2013-09-01 |
| Completed | DNA Methylation Biomarkers and Metastasis of Gastric Carcinoma Gastric Carcinoma | — | 2012-12-01 |
| Unknown | A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma Melanoma | Phase 2 | 2012-08-01 |
| Completed | Compare the Aesthetic Effect of Different Thyroidectomies Differentiated Thyroid Carcinoma (DTC) | N/A | 2012-06-01 |
| Completed | Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Ca Thyroid Cancer | N/A | 2012-01-01 |
| Completed | Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patien Breast Neoplasms, Neoplasm Metastasis | — | 2011-07-01 |
| Completed | Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma Renal Cell Carcinoma | Phase 2 | 2011-06-01 |
| Completed | Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion Breast Neoplasms, Neoplasm Metastasis, Gene Expression Profiling | — | 2010-11-01 |
| Unknown | Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Biliary Tract Cancer | Phase 2 | 2010-08-01 |
| Completed | Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC) Breast Neoplasms, Neoplasm Metastasis | — | 2010-08-01 |
| Completed | Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Nega Breast Neoplasms, Neoplasm Metastasis | — | 2010-08-01 |
| Completed | Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast Cancer Breast Neoplasm, Drug Therapy, Polymorphism,Single Nucleotide | — | 2010-08-01 |
| Completed | Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy Breast Neoplasms, Neoplasm Metastasis | — | 2010-08-01 |
| Unknown | Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis Gastric Cancer | Phase 2 | 2009-08-01 |